Some complexes of rhodium(I), rhodium(II), and rhodium(III) containing tertiary t-butylphosphines as ligands
作者:C. Masters、B. L. Shaw
DOI:10.1039/j19710003679
日期:——
Paramagnetic rhodium(II) complexes of the type trans-[RhCl2(PBut2R)2](R = Me, Et, or Prn) are formed rapidly by treating ethanolic rhodium(III) chloride trihydrate with the tertiary phosphine at 25 °C. The complexes have low magnetic moments in the solid state (<1·4 B.M.) but in solution trans-[RhCl2(PBut2Me)2] has the expected moment of ca. 2·12 B.M. Treatment of rhodiumtrichloride trihydrate with some t-butylphosphines
反式-[RhCl 2(PBu t 2 R)2 ](R = Me,Et或Pr n)型顺磁性铑(II)配合物可通过在叔膦中于3.0℃下用三水合氯化乙醇处理氯化铑(III)迅速形成。 25℃。配合物在固态(<1·4 BM)下具有较低的磁矩,但在溶液中反式-[RhCl 2(PBu t 2 Me)2 ]的预期磁矩为ca。2·12 BM用一些叔丁基膦处理三水合氯化铑(L = PBu t Pr n 2,PBu在回流的丙-2-醇中的t 2 Me,PBu t 2 Et或PBu t 2 Pr n)制得方形金字塔型氢化铑(III)络合物[RhHCl 2 L 2 ]。[RhHCl 2(PBu t Pr n 2) 2 ]与某些配体Q [Q = MeNC,MeCN,吡啶或P(OMe) 3 ]反应生成[RhHCl 2(PBu t Pr n 2) 2 Q ]。[RhHCl 2(PBu t 2 Me) 2 ]与氢气反应生成[RhH2
Preparation of polyisocyanates containing uretdione groups using phosphine catalysts
申请人:Richter Frank
公开号:US20080262262A1
公开(公告)日:2008-10-23
The invention provides a process for isocyanate dimerization (uretdione formation) and a process for preparing polyisocyanates having a high content of uretdione groups, using specific phosphines as catalysts. The phosphines have one or two tertiary alkyl radicals bound directly to phosphorus.
Die Erfindung betrifft die Verwendung von speziellen Phosphinen als Katalysatoren für die Isocyanatdimerisierung (Uretdionbildung) und ein Verfahren zur Herstellung hoch uretdiongruppenhaltiger Polyisocyanate.
Quinoline compounds as modulators of RAGE activity and uses thereof
申请人:NEW YORK UNIVERSITY
公开号:US11192859B2
公开(公告)日:2021-12-07
Quinoline compounds are disclosed that have a formula represented by the following:
and wherein Cy, R1, R4a, R4b, and n are as described herein. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, diabetes complications, inflammation, and neurodegeneration, obesity, cancer, ischemia/reperfusion injury, cardiovascular disease and other diseases related to RAGE activity.
所公开的喹啉化合物具有下式所代表的式子:
其中 Cy、R1、R4a、R4b 和 n 如本文所述。这些化合物可制备成药物组合物,并可用于预防和治疗包括人类在内的哺乳动物的各种疾病,包括非限制性的糖尿病并发症、炎症、神经变性、肥胖、癌症、缺血/再灌注损伤、心血管疾病和其他与 RAGE 活性有关的疾病。
Method for producing a polyisocyanate polymer and a polyisocyanurate plastic
申请人:COVESTRO INTELLECTUAL PROPERTY GMBH & CO. KG
公开号:US11319402B2
公开(公告)日:2022-05-03
The invention relates to a method for producing a polyisocyanate polymer and to the polyisocyanate polymer obtainable from the method and to the use thereof as part of a two-stage method for producing a polyisocyanurate plastic, in particular for producing coatings, films, semi-finished products or molded parts containing such a polyisocyanurate plastic.